MEA
Co-creating the design of risk-based managed entry agreements with payers

Discussions around risk-based managed entry agreements are growing, but only a few of these discussions come to fruition. Such agreements entail risks for both payers and manufacturers. Often, payers do not have the resources or capabilities to perform extensive risk evaluations and standardise value assessment across the board. Subsequently, many payers are sceptical of innovative […]

orphan drug
Patient advocacy as a strategy for orphan drug access

Governments have integrated incentives to accelerate and promote the approval of orphan drugs and the interest among pharmaceutical companies to develop these products is rising. However, expedited regulatory approval is by no means an assurance that orphan drugs will succeed in the marketplace.

Cell & Gene Therapies
Advances in cell and gene therapies: What does it mean for big pharma?

Recent years have seen substantial progress in the search for cell and gene therapies, with new medicinal technologies presenting hope for tackling a wide range of diseases.1 Indeed, there are some experimental therapies currently in Phase II and Phase III that are hopeful for launch into the market within the next decade.2 There is tremendous opportunity […]

Formulary Lock Out
Formulary lock out in the US

Patients in the US often hear the term ‘drug formulary’ when they go to see their physician. A formulary, essentially, is a list of prescription medicines that are readily available in the hospital or that are covered by the patient’s drug insurance plan. The contents of formularies provide a strong reflection of the business priorities […]

Market Access
Valid News, Market Access Insights – Vol 01, Issue 01

Valid News, Market Access Insights is our new newsletter. In Volume 01, Issue 01, we provide advice on how to weather pricing competition and prepare for reimbursement, as well as explain the role of confidential contracting for flexible pricing. The growing importance of patient-reported outcomes are also discussed. A global market access news round-up and […]

value added medicines
Challenges for the adoption of value added medicines

Pharmaceutical and life science companies are confronted with increasing competition while working with limited resources, driving the need to improve their internal capability to innovate. Developing new innovative products, however, requires investments, commitment, time, and product potential. How can companies simultaneously work within budget and deliver innovation and value? This dilemma is fuelling the need […]

market access training
Training for market access teams

With a growing number of companies bringing a host of new products into the healthcare market, payers are more determined than ever to scrutinise drug prices and reimbursement. Payer demands are increasingly dominating the business decision-making processes of pharmaceutical companies. Leaders in pharma are shifting their organisations away from a purely sales orientated approach towards […]

Value-Based Pricing – the way forward?

In an effort to contain costs and avoid the over-valuing of products, payer organisations in the pharmaceutical and life science industries have made price setting a standard practice. One solution that potentially prevents over-valuation of medicines is External Reference Pricing (ERP). However, with greater amounts of data due to research and technological developments, increased adoption […]

Pharma Market Access
Big data insights for market access: To trust or not to trust?

Big data reportedly houses so much clinical and commercial insight that, once unlocked, it can increase our understanding of customers and markets, while also informing the design, development, and marketing of biopharmaceutical products and services. It can also drive positive health and economic outcomes. With tremendous volumes of data, companies have more resources (in the […]

PRO data
Curbing non-adherence with PRO data

On average, it is estimated that over 50% of patients eventually abandon their treatment. Patient-reported outcomes (PROs) could facilitate efforts to reduce these figures. Defined as any data coming directly from patients about how they feel or function in relation to a health condition or its treatment – with no clinician interpretation to remove the […]